

OTRA INFORMACIÓN RELEVANTE

BIOTECHNOLOGY ASSETS, S.A.

25 de enero de 2023

En virtud de lo previsto en el artículo 228 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre, y disposiciones concordantes, así como en la Circular 3/2020 del BME MTF Equity, Biotechnology Assets, S.A. (en adelante, la “**Sociedad**”) comunica que:

BBD BioPhenix, S.L.U. (Biobide), filial 100 % de la Sociedad, ha firmado un acuerdo marco (*Master Services Agreement*) con la CRO japonesa BioSafety Research Center Inc., filial del grupo TRANS GENIC INC. Se adjunta a continuación comunicación formal del nuevo acuerdo por parte de Trans Genic Inc.

En cumplimiento de lo dispuesto en la Circular 3/2020 del BME MTF Equity se deja expresa constancia de que la información comunicada por la presente ha sido elaborada bajo la exclusiva responsabilidad de la Sociedad y sus administradores.

En Jerez de la Frontera,

Biotechnology Assets, S.A.

Víctor Manuel Infante Viñolo
Presidente del Consejo de Administración



January 25, 2023
TRANS GENIC INC.
(Code No.2342 TSE Growth Market)

BioSafety Research Center Inc. to Enter into
MASTER SERVICES AGREEMENT with Biobide

TRANS GENIC INC. (“TransGenic”) hereby announced that, on January 25, 2023, the Board of Directors of BioSafety Research Center Inc. (a subsidiary of TransGenic, President & CEO: Kenji Fukunaga, Iwata City, Shizuoka, Japan, “BSRC”) has resolved to enter into a MASTER SERVICES AGREEMENT with BBD BIOPHENIX S.L.U. (President: Victor Infante, San Sebastián, Spain, “Biobide”) on the safety and pharmacological test using zebrafish (“agreement”).

1. Purpose of agreement

BSRC provides a wide variety of safety testing service based on high Scientific reliability and contracted knockout mouse production service at full-equipped GLP (Good Laboratory Practice) and AAALAC (International Association for the Evaluation and Certification of Laboratory Animal Care) accredited facilities. It plays a central role in the drug discovery support business of TransGenic Group backed by the track record and trust accumulated over 40 years since its establishment. Especially, BSRC is one of the few domestic CRO which can conduct ecotoxicity test required for registration application for agricultural chemicals using aquatic organism, having established facilities, experienced researchers, and a good track record of contracted research service.

On the other hand, Biobide founded in 2013, is a fully owned subsidiary of Biotechnology Assets S.A., founded in 2005, which is a biotech venture company in Europe (listed in the Spanish BME Growth market. Ticker BST). Biobide is its CRO part dedicated to offer safety and efficacy assays using zebrafish under Good Laboratory Practices (GLPs).

Being recognized as a worldwide reference in zebrafish, Biobide aims to accelerate R&D process for pharmaceutical, biotech, chemical, cosmetic, and nutraceutical companies, minimizing development risks through its zebrafish services and adding value to its clients’ R&D. Biobide has the capability to develop zebrafish disease models used in the stage of preclinical studies in Drug

discovery according to the needs of its customers. In addition, Biobide has already developed customized zebrafish models of neurological diseases such as Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Duchenne or Dravet Syndrome, to name a few, and therefore it is available Drug efficacy screening services using those tailor-made models.

Under this basic agreement, both companies shall develop the Japanese market of safety and pharmacological testing services using zebrafish collaboratively, and TransGenic Group shall provide its services to Biobide.

TransGenic Group focuses on the Drug discovery support area using zebrafish stood out as next-generation drug screening technology, and already entered into a collaborative business agreement with Medical Zebrafish Therapeutics Inc. ("BSRC to Enter into Collaborative Business Agreement with Medical Zebrafish Therapeutics Inc." released on October 20, 2022), a collaborative research and development agreement with AnGes Inc. ("BSRC to Enter into Collaborative Research and Development Agreement with AnGes, Inc." released on November 10, 2022), and collaborative research agreement with Mie University ("BSRC to Enter into Collaborative Research Agreement with Mie University" released on December 26, 2022). TransGenic will provide high value-added solutions to enhance corporate value.

2. Company profile of BSRC

Name	BioSafety Research Center Inc.
Location	582-2, Shio-shinden, Iwata-City, Shizuoka, Japan
Representative	Kenji Fukunaga, President & CEO
Business description	1. Contract research and testing service on the safety of chemical substances, mainly pharmaceuticals and agrochemicals 2. Custom production of genetically engineered mice 3. Sales of mouse models and contracted non-clinical studies using them
Capital	100 million yen
Established	April, 2018

3. Company profile of Biobide

Name	BBD BIOPHENIX S.L.U. (Biobide)
Location	Gipuzkoa Scientific & Technological Park Pº Mikeletegi 56, 20009 San Sebastián, Spain

Representative	Victor Infante, President
Business description	GLP-based safety test and pharmacological test using zebrafish
Capital	203,000 EUR (equivalent to 28 million yen, at the rate of 141.852 yen per EUR as January 11, 2023)
Established	January, 2013

4. Future prospects

This matter is not expected to have a material impact on the business result or financial performance for the fiscal year 2022, however, we will immediately issue an announcement if any possibility of a material impact arises in the future.

TransGenic will expand drug discovery support business by improving CRO business in order to enhance corporate value on a mid- and long-term basis.

Contact for inquiries and additional information:

TRANS GENIC INC.

Yutaka Funabashi, Director

Telephone +81-(0)3-6551-2601